BioSpace News Archive

Fullpower Technologies, in collaboration with Stanford Sleep Medicine and UCSF Department of Psychiatry and Behavioral Sciences, presented two major studies at the SLEEP 2024 conference, furthering our understanding of sleep fragmentation and heart rate variability (HRV) during sleep.

Neuros Medical, Inc. today announced the appointment of Zach Stassen , Chief Financial Officer (CFO); Kirk Ellis, Vice President of U.S. Sales; and Steve Bosrock, Vice President of Marketing.

Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced positive results from its first-in-human CLOT OUT clinical trial evaluating the safety and performance of its Clotild® Smart Guidewire System used during mechanical thrombectomy treating ischemic stroke.

Nucleus RadioPharma today announced the closing of a Series A extension round with new investor AstraZeneca (LSE/STO/Nasdaq: AZN).

Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami.

EyePoint Pharmaceuticals, Inc. today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 3:20 p.m. ET.

Ocular Therapeutix, Inc. will host an Investor Day on Thursday, June 13, 2024.

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases, announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET.

Houston, Texas--(Newsfile Corp. - June 5, 2024) - Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings (OTC Pink: CBIH), to fund the...

Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.